Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam

Phase 1

Completed

Conditions: Japanese Healthy Adult Males

Interventions: Drug: TAK-272
Drug: Itraconazole
Drug: Digoxin
Drug: Midazolam

First Posted Date: 2015-02-25

Last Posted Date: 2016-05-23

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT02370615

An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-063
Drug: [^11C]T-773

First Posted Date: 2015-02-25

Last Posted Date: 2015-03-20

Lead Sponsor: Takeda

Target Recruit Count: 13

Registration Number: NCT02370602

A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

Phase 2

Terminated

Conditions: Hypogonadotropic Hypogonadism

Interventions: Drug: TAK-448

First Posted Date: 2015-02-24

Last Posted Date: 2017-03-31

Lead Sponsor: Takeda

Target Recruit Count: 15

Registration Number: NCT02369796

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Phase 1

Completed

Conditions: Influenza Infection

Interventions: Drug: TAK-850 0.5 mL injection
Drug: TAK-850 0.25 mL injection

First Posted Date: 2015-02-20

Last Posted Date: 2016-04-07

Lead Sponsor: Takeda

Target Recruit Count: 99

Registration Number: NCT02367885

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Phase 1

Completed

Conditions: Renal Impairment
Hepatic Impairment

Interventions: Drug: TAK-272

First Posted Date: 2015-02-20

Last Posted Date: 2017-11-06

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT02367872

Single-Dose Study of MT203

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: MT203 80 mg or matching Placebo
Drug: MT203 150mg or matching Placebo
Drug: MT203 300 mg or matching placebo

First Posted Date: 2015-02-03

Last Posted Date: 2016-06-20

Lead Sponsor: Takeda

Target Recruit Count: 32

Registration Number: NCT02354599

Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease

Phase 4

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Dexlansoprazole

First Posted Date: 2015-01-30

Last Posted Date: 2017-10-04

Lead Sponsor: Takeda

Target Recruit Count: 296

Registration Number: NCT02351960

A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: TAK-536TCH

First Posted Date: 2015-01-28

Last Posted Date: 2016-04-26

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT02348658

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: TVP-1012 1mg
Drug: TVP-1012 0.5mg
Drug: Placebo

First Posted Date: 2015-01-14

Last Posted Date: 2022-03-02

Lead Sponsor: Takeda

Target Recruit Count: 404

Registration Number: NCT02337738

A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

Phase 3

Completed

Conditions: Parkinson's Disease

Interventions: Drug: TVP-1012 1mg

First Posted Date: 2015-01-14

Last Posted Date: 2022-03-02

Lead Sponsor: Takeda

Target Recruit Count: 198

Registration Number: NCT02337751

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy